NEW DELHI – The Indian biotech firm Biocon Ltd. plans to buy back a stake in its research unit, Syngene, now held by GE Capital. The rapidly growing subsidiary represents more than a quarter of Biocon's revenues.
NEW DELHI – India's expected share in the global market for biosimilars is between 20 percent and 25 percent in the next five years, but analysts caution that the country needs to improve its funding, innovation capabilities and regulation for large molecule drugs.
NEW DELHI – India's expected share in the global market for biosimilars is between 20 percent and 25 percent in the next five years, but analysts caution that the country needs to improve its funding, innovation capabilities and regulation for large molecule drugs.
NEW DELHI – India's Central Drugs Standard Control Organisation (CDSCO) announced plans to set up an online system for submission of information on clinical trials.
NEW DELHI – India's Central Drugs Standard Control Organisation (CDSCO) announced plans to set up an online system for submission of information on clinical trials.
NEW DELHI – Indian biopharma company Vyome Biosciences raised almost $8 million in a second round of fundraising as part of a push to develop treatments for hard-to-treat skin conditions such as acne, persistent dandruff and bacterial and fungal skin infections.
NEW DELHI – Indian biopharma company Vyome Biosciences raised almost $8 million in a second round of fundraising as part of a push to develop treatments for hard-to-treat skin conditions such as acne, persistent dandruff and bacterial and fungal skin infections.
NEW DELHI – The first budget of India's newly elected government included some nice surprises for India's biotechnology sector in the form of international collab-orations and a new bioclusters initiative.
